Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics plc (Nasdaq: AUTL) generates frequent news as an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies for cancer and autoimmune disease. News coverage for AUTL often centers on AUCATZYL® (obecabtagene autoleucel; obe-cel), the company’s CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and on the clinical and commercial progress of this product.
Investors and healthcare observers following Autolus news will see updates on AUCATZYL net product revenue, treatment center activation, and reimbursement developments such as NICE recommendations and conditional marketing authorizations in the UK and EU. Press releases also describe real-world data from consortia like ROCCA, which evaluate safety and response rates for AUCATZYL in clinical practice, alongside analyses from the FELIX study that explore CAR T-cell persistence and product cell phenotypes as potential predictors of long-term outcomes.
Autolus regularly reports clinical data from its broader pipeline, including the CATULUS trial in pediatric relapsed or refractory B-ALL, the CARLYSLE Phase 1 study in severe refractory systemic lupus erythematosus, the LUMINA Phase 2 trial in lupus nephritis and the BOBCAT trial in progressive multiple sclerosis. These updates typically highlight remission rates, safety profiles, B-cell depletion and immune reset signals in autoimmune indications. Additional news items cover collaborations, such as the evaluation of Cellares’ automated Cell Shuttle platform to support high-throughput CAR T manufacturing, and corporate developments including leadership appointments and participation in healthcare conferences.
This news page allows readers to track Autolus’ ongoing clinical milestones, regulatory and reimbursement decisions, manufacturing initiatives and financial disclosures related to its T cell therapy programs. For those monitoring AUTL, the flow of updates provides context on how AUCATZYL and pipeline candidates are progressing across hematologic malignancies, solid tumors and autoimmune diseases.
Autolus Therapeutics (Nasdaq: AUTL) will participate in two investor events in March 2026. The company will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2028 at 11:10am EST / 4:10pm GMT, with CEO Dr. Christian Itin presenting and a webcast available. A replay will be archived for 90 days. Management will host investor meetings at Jefferies Biotech on the Beach Summit on March 10, 2026 in Miami, FL.
Autolus Therapeutics (Nasdaq: AUTL) granted inducement stock options totaling 113,650 ADS to 22 employees under its 2025 Inducement Plan, with a grant date of January 26, 2026 and an exercise price of $1.46 per share. Each option has a 10-year term and vests over four years (25% after one year, then monthly over 36 months), subject to continued service. The awards were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Autolus (NASDAQ: AUTL) reported preliminary unaudited AUCATZYL® (obe-cel) net product revenue of approximately $24M for Q4 2025 and $75M for full-year 2025, and issued 2026 revenue guidance of $120M–$135M. Independent ROCCA real-world data confirmed strong clinical activity and a favorable safety profile. Key clinical updates include a 95.5% ORR in pediatric r/r B-ALL (CATULUS Phase 1) and selection of 50M cells as the Phase 2 dose in lupus nephritis (LUMINA). The company expects positive gross margin in 2026 and sufficient cash to fund operations into Q4 2027.
Autolus (NASDAQ: AUTL) will evaluate Cellares’ fully automated Cell Shuttle platform to complement commercial manufacturing of AUCATZYL® (obe-cel) at its Nucleus facility in Stevenage, UK.
The Cell Shuttle integrates CAR T unit operations in a single-use cartridge and can process up to 16 patient batches in parallel, with an architecture Cellares says can deliver up to 10-fold higher throughput versus conventional facilities. Cellares pairs this with Cell Q for automated, high-throughput QC and holds the FDA AMT designation.
Autolus (NASDAQ: AUTL) presented updated Phase 1 CARLYSLE data for obe-cel in severe refractory systemic lupus erythematosus (srSLE) at ASH on Dec 8, 2025.
Nine adults were infused (six at 50×10^6 cells, three at 100×10^6). At 50M, CRR 50% (3/6) and DORIS 83% (5/6) were reported with median DORIS onset 5.1 months and median follow-up 12 months. All patients showed deep B-cell depletion; median CAR T-cell persistence was 3.0 months and peak expansion at a median of 10 days. Safety: no DLTs at 50M, no ICANS, Grade 1 CRS in three patients at 50M and three at 100M; one transient Grade 3 liver toxicity in 100M cohort; hypertension observed in five patients at 50M.
50M chosen as recommended Phase 2 dose; LUMINA Phase 2 in lupus nephritis with registrational intent is now enrolling and aligned with FDA.
Autolus (NASDAQ: AUTL) presented clinical and real-world data on obecabtagene autoleucel (obe-cel) at ASH 2025 showing high remission rates and a favorable safety profile. In pediatric CATULUS data (n=21) the overall response rate was 95.5% with 90.9% CR, and high‑grade CRS and ICANS each occurred in 8.7% of patients; median follow-up was 8.8 months. FELIX post-hoc analyses found CAR T persistence at Month 3 (75.9%) associated with longer EFS and OS. Product cell phenotype (higher Tcm %) correlated with better outcomes. Real-world ROCCA data during the US launch mirrored low rates of high‑grade CRS and ICANS.
Autolus Therapeutics (Nasdaq: AUTL) announced the appointment of Ryan Richardson to its Board of Directors effective Dec 1, 2025.
Mr. Richardson brings more than 20 years of strategy and corporate development experience, including service as Chief Strategy Officer and management board member at BioNTech from Sept 2018 to Sept 2025. The company said his background in corporate development, capital markets, IPOs, financings and M&A will support Autolus' transition as a commercial-stage company and advance commercial launch and expansion efforts for obe-cel.
His prior roles include Executive Director at J.P. Morgan Global Healthcare Investment Banking (2011–2018) and chairmanship at Instadeep following BioNTech's 2023 acquisition.
Autolus Therapeutics (Nasdaq: AUTL) announced that NICE published draft guidance recommending AUCATZYL® (obecabtagene autoleucel) as a treatment option for adult patients aged ≥26 years with relapsed or refractory B‑cell precursor acute lymphoblastic leukemia (r/r B‑ALL).
AUCATZYL will be available through routine commissioning by the NHS in England and Wales and Autolus intends to launch imminently while pursuing Scottish access. The MHRA granted conditional marketing authorisation in April 2025, based on the FELIX study published in the New England Journal of Medicine in November 2024.
Autolus Therapeutics (Nasdaq: AUTL) will participate in the Jefferies Global Healthcare Conference in London. CEO Dr. Christian Itin will appear in a fireside chat on Tuesday, November 18, 2025 at 7:30 AM EST / 12:30 PM GMT. A live webcast will be available on the company’s Events page and a replay will be archived on the website for 90 days after the presentation.
The presentation covers company updates and investor engagement; webcast access is via the company investor relations site.
Autolus Therapeutics (Nasdaq: AUTL) reported Q3 2025 results and operational updates on Nov 12, 2025. Key commercial metrics: Q3 net product revenue $21.1M, deferred revenue $7.6M, and 60 U.S. treatment centers activated as of Nov 12, 2025. Cash and marketable securities totaled $367.4M at Sept 30, 2025.
Clinical highlights include rmAT designation for obe-cel in pediatric r/r B-ALL, CARLYSLE Phase 1 data in severe refractory SLE showing DORIS remission in 83% (5/6) and CRR in 50% (3/6), and first patient dosed in a progressive MS Phase 1 trial. Management additions announced to support commercialization and manufacturing.